Gradual accumulation of tau in the brain has been widely identified as a biomarker of various neurodegenerative diseases that are collectively known as tauopathies, including AD, frontotemporal dementias (FTD), Parkinson's disease (PD) and amyolateral sclerosis (ALS) [157,158,159,160,161]. Here, MAPT is linked to tauopathy.